ELTX

Elicio Therapeutics Inc. (ELTX) | Rumor.io

Elicio Therapeutics

ELTX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,447

Bullish sentiment (50-day avg)90%

Price to earnings ratio5.75

Market capitalization48.6M

Earnings per share-2.15

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39.6M

Social

What share of all stock conversation is about ELTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Jul 8

Elicio Therapeutics, Inc. ($ELTX) is experiencing a strong intraday push, trading near $3.55 after bouncing from the $2.80 area.
The company's stock is still a rebound attempt, not a confirmed reversal, with a key level at $3.67, a clean break over which could open the door toward $4.
A recent capital raise by Elicio Therapeutics has sparked a classic biotech dilution move, with the company's stock spiking on the news.

Generated by AI

Sentiment

Of the messages about ELTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -50	82.82% -8.53
Bearish	—	—	50% new	17.18% +8.53

Bullish· Jun 18

$ELTX has a strong momentum with a 70.7% increase, making it a promising investment opportunity.
The company's recent news, including a presentation on June 24th, is expected to lead to an upgrade from analysts and a potential surge in price.
Insiders are likely to buy aggressively after the company's responses to the government's funding, leading to a significant increase in the stock price.

Bearish· Jun 23

$ELTX has a high short interest of nearly 42% and 150% borrow fees, making it an attractive target for short sellers.
The company's conference on June 24, 2026, could lead to sharp movements in the stock price as short sellers may not want to be in the position if the conference goes well.
The high borrowing fees, currently at 222-227%, could lead to a catastrophic short squeeze if the company secures funding or experiences buying pressure, resulting in a significant stock price increase.

Generated by AI

Topics

Of the messages about ELTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	77.84%
Technical Analysis	—	0%	0%	15.27%
Analysts	—	0%	0%	3.91%
Controversies	—	0%	0%	1.3%
Earnings	—	0%	0%	1.68%
Macro	—	0%	0%	0%

Jun 17

Elicio Therapeutics reports complete responses in 3 patients with metastatic mKRAS pancreatic cancer after treatment with ELI-002 7P followed by checkpoint inhibitors.
The company plans to conduct a Phase 1 combination study to further evaluate the efficacy of ELI-002 7P with checkpoint inhibitors in pancreatic cancer.
The complete responses were observed in patients with microsatellite stable (MSS) or mismatch repair proficient tumors, which is a notable outcome given the poor prognosis of this patient population.

Generated by AI

Community

Of the messages about ELTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	83.33%	88%	31.91%
Newcomers	—	16.67%	12%	68.09%

Jun 18

Newcomers to $ELTX are focused on the company's failed trial and the need for new funding, with some mentioning the potential for a drop in price due to this.
Others are concerned about the company's low insider ownership and the possibility of a pump and dump scheme, with some speculating about the timing of a potential offering.
A few are tracking the stock's momentum and using technical analysis to identify potential entry and exit points, with one user even creating a visual representation of the stock's movement.

Generated by AI

New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancerFindings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified ana

6d agoYahoo Finance UK

B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating

Elicio Therapeutics (ELTX) has an average rating of buy and mean price target of $19.13, according t

6d agoYahoo Finance

Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines

Detailed price information for Elicio Therapeutics Inc (ELTX-Q) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer

15d agoInvesting.com

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. H.C

1mo agoYahoo Finance

Also Discussed

Investors talking about ELTX also mention

#	Name	Attention
1	Abivax SAABVX	0.01%-0.01
2	Compass Therapeutics, Inc.CMPX	0%new
3	Celcuity Inc.CELC	0%0
4	Smith Douglas Homes CorporationSDHC	0%0
5	Hagerty, Inc.HGTY	0%new
6	ANGN - Angion Biomedica Corp.	——
7	Vanguard Global ex-US Real Estate Index FundVNQI	0%0
8	Universal Electronics Inc.UEIC	0%0
9	Transcontinental Realty Investors, Inc.TCI	0%0
10	OptimizeRx CorporationOPRX	0%0

Elicio Therapeutics Inc.

Healthcare
Biotechnology

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response. Its programs include investigational therapies for KRAS-driven cancers, BRAF-driven cancers, and other mutation-defined tumor types, alongside broader efforts in cancer immunotherapy and selected infectious disease applications. Elicio Therapeutics Inc. works at the intersection of oncology and immune system engineering, using platform-based drug design to create both personalized and off-the-shelf candidates for clinically important targets. Headquartered in Boston, Massachusetts, Elicio Therapeutics Inc. is positioned as a specialized player in the biotechnology market with a focus on hard-to-treat cancers and precision immunotherapy approaches.

Website

Location

451 D Street

Boston, MA, 02210

United States

Social

What share of all stock conversation is about ELTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Jul 8

Elicio Therapeutics, Inc. ($ELTX) is experiencing a strong intraday push, trading near $3.55 after bouncing from the $2.80 area.
The company's stock is still a rebound attempt, not a confirmed reversal, with a key level at $3.67, a clean break over which could open the door toward $4.
A recent capital raise by Elicio Therapeutics has sparked a classic biotech dilution move, with the company's stock spiking on the news.

Generated by AI

Sentiment

Of the messages about ELTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -50	82.82% -8.53
Bearish	—	—	50% new	17.18% +8.53

Bullish· Jun 18

$ELTX has a strong momentum with a 70.7% increase, making it a promising investment opportunity.
The company's recent news, including a presentation on June 24th, is expected to lead to an upgrade from analysts and a potential surge in price.
Insiders are likely to buy aggressively after the company's responses to the government's funding, leading to a significant increase in the stock price.

Bearish· Jun 23

$ELTX has a high short interest of nearly 42% and 150% borrow fees, making it an attractive target for short sellers.
The company's conference on June 24, 2026, could lead to sharp movements in the stock price as short sellers may not want to be in the position if the conference goes well.
The high borrowing fees, currently at 222-227%, could lead to a catastrophic short squeeze if the company secures funding or experiences buying pressure, resulting in a significant stock price increase.

Generated by AI

Topics

Of the messages about ELTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	77.84%
Technical Analysis	—	0%	0%	15.27%
Analysts	—	0%	0%	3.91%
Controversies	—	0%	0%	1.3%
Earnings	—	0%	0%	1.68%
Macro	—	0%	0%	0%

Jun 17

Elicio Therapeutics reports complete responses in 3 patients with metastatic mKRAS pancreatic cancer after treatment with ELI-002 7P followed by checkpoint inhibitors.
The company plans to conduct a Phase 1 combination study to further evaluate the efficacy of ELI-002 7P with checkpoint inhibitors in pancreatic cancer.
The complete responses were observed in patients with microsatellite stable (MSS) or mismatch repair proficient tumors, which is a notable outcome given the poor prognosis of this patient population.

Generated by AI

Community

Of the messages about ELTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	83.33%	88%	31.91%
Newcomers	—	16.67%	12%	68.09%

Jun 18

Newcomers to $ELTX are focused on the company's failed trial and the need for new funding, with some mentioning the potential for a drop in price due to this.
Others are concerned about the company's low insider ownership and the possibility of a pump and dump scheme, with some speculating about the timing of a potential offering.
A few are tracking the stock's momentum and using technical analysis to identify potential entry and exit points, with one user even creating a visual representation of the stock's movement.

Generated by AI

Elicio Therapeutics

Social

Jul 8

Sentiment

Bullish· Jun 18

Bearish· Jun 23

Topics

Jun 17

Community

Jun 18

News

Elicio to present new pancreatic cancer trial data at ESMO

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating

Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines

Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Elicio Therapeutics Inc.

Company Information

Location

News

Elicio to present new pancreatic cancer trial data at ESMO

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating

Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines

Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Social

Jul 8

Sentiment

Bullish· Jun 18

Bearish· Jun 23

Topics

Jun 17

Community

Jun 18